Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to two newly hired non-executive employees on May 1, 2025. The options cover 5,000 shares of common stock at an exercise price of $14.46 per share, matching the closing price on the Nasdaq Global Select Market on the grant date. The options were granted under the company's 2021 Inducement Plan and will vest in three equal annual installments over three years, contingent on continuous service. The options expire after ten years and were approved as material inducement for employment compensation.

News Market Reaction

+4.73%

1 alert

+4.73% News Effect

On the day this news was published, ANIK gained 4.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com

FAQ

What stock options did Anika Therapeutics (ANIK) grant to new employees in May 2025?

Anika granted non-statutory stock options for 5,000 shares at $14.46 per share to two new non-executive employees on May 1, 2025.

What is the vesting schedule for ANIK's May 2025 employee stock options?

The stock options vest in three equal annual installments over three years, with one-third vesting on each anniversary of the grant date, subject to continuous employment.

When do the ANIK stock options granted in May 2025 expire?

The stock options expire on the tenth anniversary of the grant date (May 1, 2035), unless terminated earlier according to their terms.

Under which plan were the ANIK May 2025 stock options granted?

The options were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.